Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug targets Antibody-Producing cells in brain inflammation

NCT ID NCT03993262

Recruiting now Disease control Sponsor: Jena University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether bortezomib, a drug that targets antibody-producing cells, can help people with severe autoimmune encephalitis. In this condition, the body's own antibodies attack the brain. The study will enroll 50 adults who have already tried another treatment (rituximab). Participants will receive either bortezomib or a placebo, along with dexamethasone, and be followed for 17 weeks to see if their symptoms improve.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
bortezomib
What this could lead to
If it works, this could provide a more targeted treatment for severe autoimmune encephalitis by directly attacking the cells that produce harmful antibodies.
What could go wrong
This is a small, early-phase trial with only 50 participants, so results may not apply to everyone. Bortezomib also has side effects like nerve damage and low blood cell counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE ENCEPHALITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease autoimmune disorder of the nervous system autoimmune encephalitis encephalitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE ENCEPHALITIS

Contacts and locations

Locations

  • Charité - Universitätsmedizin Berlin, Klinik für Neurologie mit Experimenteller Neurologie

    RECRUITING

    Berlin, 10117, Germany

  • Klinik für Neurologie UKSH, Campus Kiel

    RECRUITING

    Kiel, 24105, Germany

  • Ludwig-Maximilians-Universität München, Klinikum Großhadern

    RECRUITING

    München, Bavaria, 81377, Germany

  • Medizinische Hochschule Hannover

    RECRUITING

    Hanover, Niedersachen, 30625, Germany

  • Ruhr-Universität Bochum, St. Josef Hospital, Klinik für Neurologie

    RECRUITING

    Bochum, 44791, Germany

  • University Hospital Düsseldorf, Clinic for Neurology

    RECRUITING

    Düsseldorf, 40225, Germany

  • University Hospital Frankfurt (Main), Clinic for Neurology

    RECRUITING

    Frankfurt, 60528, Germany

  • Universitätsklinikum Erlangen, Neurologische Klinik

    RECRUITING

    Erlangen, 91054, Germany

  • Universitätsklinikum Essen (AöR), Klinik für Neurologie

    RECRUITING

    Essen, 45147, Germany

  • Universitätsklinikum Jena, Sektion Translationale Neuroimmunologie, Klinik für Neurologie

    RECRUITING

    Jena, Germany, 07747, Germany

  • Universitätsklinikum Leipzig, Klinik und Poliklinik für Neurologie

    RECRUITING

    Leipzig, 04103, Germany

  • Universitätsklinikum Münster Klinik für Neurologie

    RECRUITING

    Münster, 48149, Germany

  • Universitätsklinikum Ulm, Klinik für Neurologie Neurologische Ambulanz

    RECRUITING

    Ulm, 89081, Germany

  • Universitätsklinikum Würzburg

    RECRUITING

    Würzburg, Bavaria, 97080, Germany

  • Universitätsmedizin Greifswald, Klinik und Poliklinik für Neurologie

    RECRUITING

    Greifswald, 17475, Germany

  • Universitätsmedizin Göttingen Georg-August-Universität, Klinik für Neurologie

    RECRUITING

    Göttingen, 37075, Germany

  • Universitätsmedizin Mainz, Klinik und Poliklinik für Neurologie

    RECRUITING

    Mainz, 55131, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.